

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

RRID:AB_443425

Type: Antibody

Proper Citation

Abcam Cat# ab16669, RRID:AB_443425

Antibody Information

URL: http://antibodyregistry.org/AB_443425

Proper Citation: Abcam Cat# ab16669, RRID:AB_443425

Target Antigen: CD3

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry; Western Blot; Immunohistochemistry-Fr, Immunohistochemistry-P, Western Blot

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

Description: This monoclonal targets CD3

Target Organism: feline, simian, canine, baboon, horse, mouse, cat, human, dog

Clone ID: Clone SP7

Antibody ID: AB_443425

Vendor: Abcam

Catalog Number: ab16669

Record Creation Time: 20250820T042639+0000

Record Last Update: 20250820T185909+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 147 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhao S, et al. (2025) NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer. *eLife*, 13.

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. *Cell reports. Medicine*, 6(9), 102298.

Xing X, et al. (2025) Pan-cancer human brain metastases atlas at single-cell resolution. *Cancer cell*, 43(7), 1242.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Tang R, et al. (2025) Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. *Gastroenterology*, 169(4), 615.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. *Cell reports*, 44(10), 116404.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Kouzu K, et al. (2025) AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. *Esophagus : official journal of the Japan Esophageal Society*.

Hu SW, et al. (2025) Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer. *Cell reports. Medicine*, 6(11), 102429.

Tai KY, et al. (2025) Adipocyte lipolysis activates epithelial stem cells for hair regeneration through fatty acid metabolic signaling. *Cell metabolism*, 37(11), 2202.

Jiang T, et al. (2025) CD8+MT+ effector T cells from enlarged tumor-draining lymph nodes enhanced anti-tumor immunity and improved prognosis in colorectal cancer. *Cell reports*, 44(12), 116625.

Engel K, et al. (2025) Segment specific loss of NFAT5 function in the kidneys is sufficient to induce a global kidney injury like phenotype. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(2), e70352.

Wang YQ, et al. (2025) Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology. *Cell reports. Medicine*, 6(4), 102030.

Schubert C, et al. (2025) Neuroinflammation causes mitral cell dysfunction and olfactory impairment in a multiple sclerosis model. *Journal of neuroinflammation*, 22(1), 71.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. *Journal for immunotherapy of cancer*, 13(5).

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. *Cell reports. Medicine*, 6(11), 102434.

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. *Cell reports. Medicine*, 6(7), 102201.

Wang F, et al. (2025) Pseudouridine synthase 1-targeted therapy activates antiviral immunity to boost cancer immunotherapy. *Cell reports*, 44(9), 116233.

Zhao R, et al. (2025) Targeting AQP5-mediated arginine deprivation in gastric cancer stem cells restores NK cell anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102333.

Jia H, et al. (2025) DNA methylation mediates the immunosuppressive tumour microenvironment in metastatic endometrial clear cell carcinoma. *EBioMedicine*, 120, 105954.